235 related articles for article (PubMed ID: 35968955)
41. Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease.
Li G; Lin J; Zhang C; Gao H; Lu H; Gao X; Zhu R; Li Z; Li M; Liu Z
Gut Microbes; 2021; 13(1):1968257. PubMed ID: 34494943
[TBL] [Abstract][Full Text] [Related]
42. 10-Phenyltriazoyl Artemisinin is a Novel P-glycoprotein Inhibitor that Suppresses the Overexpression and Function of P-glycoprotein.
Lee DH; Hasanuzzaman M; Kwon D; Choi HY; Kim SM; Kim DJ; Kang DJ; Hwang TH; Kim HH; Shin HJ; Shin JG; Oh S; Lee S; Kim SW
Curr Pharm Des; 2018; 24(46):5590-5597. PubMed ID: 30799787
[TBL] [Abstract][Full Text] [Related]
43. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
Troutman MD; Thakker DR
Pharm Res; 2003 Aug; 20(8):1210-24. PubMed ID: 12948019
[TBL] [Abstract][Full Text] [Related]
44. Regulation of P-Glycoprotein in the Brain.
Chai AB; Callaghan R; Gelissen IC
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498995
[TBL] [Abstract][Full Text] [Related]
45. Postnatal growth retardation is associated with deteriorated intestinal mucosal barrier function using a porcine model.
Qi M; Tan B; Wang J; Liao S; Li J; Cui Z; Shao Y; Ji P; Yin Y
J Cell Physiol; 2021 Apr; 236(4):2631-2648. PubMed ID: 32853405
[TBL] [Abstract][Full Text] [Related]
46. Optimized Hepatocyte-Like Cells with Functional Drug Transporters Directly-Reprogrammed from Mouse Fibroblasts and their Potential in Drug Disposition and Toxicology.
Wu ZT; Yao D; Ji SY; Ni X; Gao YM; Hui LJ; Pan GY
Cell Physiol Biochem; 2016; 38(5):1815-30. PubMed ID: 27160211
[TBL] [Abstract][Full Text] [Related]
47. Regional difference in intestinal drug absorption as a measure for the potential effect of P-glycoprotein efflux transporters.
Ashmawy SM; El-Gizawy SA; El Maghraby GM; Osman MA
J Pharm Pharmacol; 2019 Mar; 71(3):362-370. PubMed ID: 30362574
[TBL] [Abstract][Full Text] [Related]
48. Crohn's Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression.
Wilson A; Urquhart BL; Ponich T; Chande N; Gregor JC; Beaton M; Kim RB
Mol Pharm; 2019 Sep; 16(9):4059-4064. PubMed ID: 31393129
[TBL] [Abstract][Full Text] [Related]
49. Caffeic Acid Attenuates Multi-Drug Resistance in Cancer Cells by Inhibiting Efflux Function of Human P-glycoprotein.
Teng YN; Wang CCN; Liao WC; Lan YH; Hung CC
Molecules; 2020 Jan; 25(2):. PubMed ID: 31936160
[No Abstract] [Full Text] [Related]
50. A revised role for P-glycoprotein in the brain distribution of dexamethasone, cortisol, and corticosterone in wild-type and ABCB1A/B-deficient mice.
Mason BL; Pariante CM; Thomas SA
Endocrinology; 2008 Oct; 149(10):5244-53. PubMed ID: 18556350
[TBL] [Abstract][Full Text] [Related]
51. Up-regulation of P-gp via NF-κB activation confers protection against oxidative damage in the retinal pigment epithelium cells.
Feng Q; Yang W; Gao Z; Ruan X; Zhang Y
Exp Eye Res; 2019 Apr; 181():367-373. PubMed ID: 30496729
[TBL] [Abstract][Full Text] [Related]
52. Effect of various antibiotics on modulation of intestinal microbiota and bile acid profile in mice.
Zhang Y; Limaye PB; Renaud HJ; Klaassen CD
Toxicol Appl Pharmacol; 2014 Jun; 277(2):138-45. PubMed ID: 24657338
[TBL] [Abstract][Full Text] [Related]
53. P-glycoprotein Substrate Assessment in Drug Discovery: Application of Modeling to Bridge Differential Protein Expression Across In Vitro Tools.
Li N; Kulkarni P; Badrinarayanan A; Kefelegn A; Manoukian R; Li X; Prasad B; Karasu M; McCarty WJ; Knutson CG; Gupta A
J Pharm Sci; 2021 Jan; 110(1):325-337. PubMed ID: 32946896
[TBL] [Abstract][Full Text] [Related]
54. Overexpression of mdr2 gene by peroxisome proliferators in the mouse liver.
Miranda S; Vollrath V; Wielandt AM; Loyola G; Bronfman M; Chianale J
J Hepatol; 1997 Jun; 26(6):1331-9. PubMed ID: 9210621
[TBL] [Abstract][Full Text] [Related]
55. Approaches to minimize the effects of P-glycoprotein in drug transport: A review.
Husain A; Makadia V; Valicherla GR; Riyazuddin M; Gayen JR
Drug Dev Res; 2022 Jun; 83(4):825-841. PubMed ID: 35103340
[TBL] [Abstract][Full Text] [Related]
56. Possible Regulation of P-glycoprotein Function by Adrenergic Agonists in a Vascular-luminal Perfused Preparation of Small Intestine.
Mukai H; Takanashi M; Ogawara KI; Maruyama M; Higaki K
J Pharm Sci; 2021 Dec; 110(12):3889-3895. PubMed ID: 34530005
[TBL] [Abstract][Full Text] [Related]
57. Regulation of biliary drug efflux pump expression by hormones and xenobiotics.
Fardel O; Payen L; Courtois A; Vernhet L; Lecureur V
Toxicology; 2001 Oct; 167(1):37-46. PubMed ID: 11557128
[TBL] [Abstract][Full Text] [Related]
58. The Xenobiotic Transporter Mdr1 Enforces T Cell Homeostasis in the Presence of Intestinal Bile Acids.
Cao W; Kayama H; Chen ML; Delmas A; Sun A; Kim SY; Rangarajan ES; McKevitt K; Beck AP; Jackson CB; Crynen G; Oikonomopoulos A; Lacey PN; Martinez GJ; Izard T; Lorenz RG; Rodriguez-Palacios A; Cominelli F; Abreu MT; Hommes DW; Koralov SB; Takeda K; Sundrud MS
Immunity; 2017 Dec; 47(6):1182-1196.e10. PubMed ID: 29262351
[TBL] [Abstract][Full Text] [Related]
59. Regional difference in P-glycoprotein function in rat intestine.
Iida A; Tomita M; Hayashi M
Drug Metab Pharmacokinet; 2005 Apr; 20(2):100-6. PubMed ID: 15855720
[TBL] [Abstract][Full Text] [Related]
60. Drug resistance via radixin-mediated increase of P-glycoprotein membrane expression during SNAI1-induced epithelial-mesenchymal transition in HepG2 cells.
Kamioka H; Edaki K; Kasahara H; Tomono T; Yano K; Ogihara T
J Pharm Pharmacol; 2021 Dec; 73(12):1609-1616. PubMed ID: 34313784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
